BUZZ-Annovis Bio falls on planned $50 mln share sale** Drug developer Annovis Bio's ANVS.N shares fall 4.6% to $5.40 premarket
** ANVS files for up to $50 mln "at-the-market" stock sale agreement to be handled by Oppenheimer
** Co plans to use the proceeds for general corporate purposes, including the development of its lead experimental drug buntanetap
** ANVS set to host its year-end investor webcast late Wednesday
** ANVS has 13.8 mln outstanding shares and $78 mln market capitalization - LSEG data
** As of last close, ANVS shares down 69.7% YTD
(Reporting by Arasu Kannagi Basil in Bengaluru)
((ArasuKannagi.Basil@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments